LifeMD Shares Rise After Offering Lilly's GLP-1 Obesity Pill

Dow Jones

04/21

By Elias Schisgall

Shares of LifeMD rose after the telehealth company said it is offering Eli Lilly's GLP-1 obesity pill, Foundayo, through its weight management program.

Shares were up 12% to $4.59 on Monday. The stock is up 35% this year.

LifeMD said eligible patients in its weight management program could receive Foundayo through the company's integration with LillyDirect, Eli Lilly's direct-to-consumer platform. Initial dosages begin at $149 a month.

"By working with LillyDirect, we are able to offer eligible patients streamlined access to this therapy at an accessible price point," Chief Executive Justin Schreiber said. "LifeMD remains dedicated to expanding access to high-quality, affordable weight management care, and the addition of Foundayo to our platform furthers that commitment."

LifeMD offers GLP-1 treatments from both Lilly and Novo Nordisk, the company said.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

April 20, 2026 12:15 ET (16:15 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2629885727"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2629885727\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2629885727?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-21 00:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629885727","market":"fut","top_or_hot":-1,"title":"LifeMD Shares Rise After Offering Lilly's GLP-1 Obesity Pill","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of LifeMD rose after the telehealth company said it is offering Eli Lilly's GLP-1 obesity pill, Foundayo, through its weight management program. \n</p>\n<p>\n  Shares were up 12% to $4.59 on Monday. The stock is up 35% this year. \n</p>\n<p>\n  LifeMD said eligible patients in its weight management program could receive Foundayo through the company's integration with LillyDirect, Eli Lilly's direct-to-consumer platform. Initial dosages begin at $149 a month. \n</p>\n<p>\n  \"By working with LillyDirect, we are able to offer eligible patients streamlined access to this therapy at an accessible price point,\" Chief Executive Justin Schreiber said. \"LifeMD remains dedicated to expanding access to high-quality, affordable weight management care, and the addition of Foundayo to our platform furthers that commitment.\" \n</p>\n<p>\n  LifeMD offers GLP-1 treatments from both Lilly and <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 20, 2026 12:15 ET (16:15 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LifeMD Shares Rise After Offering Lilly's GLP-1 Obesity Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLifeMD Shares Rise After Offering Lilly's GLP-1 Obesity Pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-21 00:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of LifeMD rose after the telehealth company said it is offering Eli Lilly's GLP-1 obesity pill, Foundayo, through its weight management program. \n</p>\n<p>\n  Shares were up 12% to $4.59 on Monday. The stock is up 35% this year. \n</p>\n<p>\n  LifeMD said eligible patients in its weight management program could receive Foundayo through the company's integration with LillyDirect, Eli Lilly's direct-to-consumer platform. Initial dosages begin at $149 a month. \n</p>\n<p>\n  \"By working with LillyDirect, we are able to offer eligible patients streamlined access to this therapy at an accessible price point,\" Chief Executive Justin Schreiber said. \"LifeMD remains dedicated to expanding access to high-quality, affordable weight management care, and the addition of Foundayo to our platform furthers that commitment.\" \n</p>\n<p>\n  LifeMD offers GLP-1 treatments from both Lilly and <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 20, 2026 12:15 ET (16:15 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4144","symbol_name":"石油与天然气的储存和运输","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629885727","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629885727","pubTimestamp":1776701700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of LifeMD rose after the telehealth company said it is offering Eli Lilly's GLP-1 obesity pill, Foundayo, through its weight management program.Shares were up 12% to $4.59 on Monday. The stock is up 35% this year.LifeMD said eligible patients in its weight management program could receive Foundayo through the company's integration with LillyDirect, Eli Lilly's direct-to-consumer platform. Initial dosages begin at $149 a month.\"By working with LillyDirect, we are able to offer eligible patients streamlined access to this therapy at an accessible price point,\" Chief Executive Justin Schreiber said. \"LifeMD remains dedicated to expanding access to high-quality, affordable weight management care, and the addition of Foundayo to our platform furthers that commitment.\". LifeMD offers GLP-1 treatments from both Lilly and Novo Nordisk, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4144":"石油与天然气的储存和运输","LFMD":"LifeMD Inc.","BK4590":"PTP","BK4183":"个人用品","GLP":"Global Partners Lp","BK4167":"医疗保健技术"},"translate_title":"LifeMD提供礼来公司GLP-1减肥药后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLP":1.5,"LFMD":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of LifeMD rose after the telehealth company said it is offering Eli Lilly's GLP-1 obesity pill, Foundayo, through its weight management program. \n\n\n  Shares were up 12% to $4.59 on Monday. The stock is up 35% this year. \n\n\n  LifeMD said eligible patients in its weight management program could receive Foundayo through the company's integration with LillyDirect, Eli Lilly's direct-to-consumer platform. Initial dosages begin at $149 a month. \n\n\n  \"By working with LillyDirect, we are able to offer eligible patients streamlined access to this therapy at an accessible price point,\" Chief Executive Justin Schreiber said. \"LifeMD remains dedicated to expanding access to high-quality, affordable weight management care, and the addition of Foundayo to our platform furthers that commitment.\" \n\n\n  LifeMD offers GLP-1 treatments from both Lilly and Novo Nordisk, the company said. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 20, 2026 12:15 ET (16:15 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}